No Carolina / NY / Florida
Ph: 561.316.3330

No Carolina | NY | Florida

Intelivation Technologies Launches Advantage-C™ PEEK Cervical Interbody Fusion Device

Editor: What To Know

  • Intelivation Technologies, a medical device company with a growing product portfolio announced today that they are officially launching the Advantage-C™ PEEK Interbody Fusion Device during the 36th Annual NASS Meeting in Boston, September 29-October 2, 2021.
  • The Advantage-C™ PEEK Cervical Interbody fusion device is designed to be used in skeletally mature patients in levels C2-T1 in conjunction with fixation for ACDF (anterior cervical discectomy and fusion) procedures.
  • President Amit Sinha stated, “We are looking forward to a successful launch of Advantage-C™ and the myriad of efficiencies this device will bring to both surgeons and hospital systems”.

Intelivation Technologies, a medical device company with a growing product portfolio announced today that they are officially launching the Advantage-C™ PEEK Interbody Fusion Device during the 36th Annual NASS Meeting in Boston, September 29-October 2, 2021.

The Advantage-C™ PEEK Cervical Interbody fusion device is designed to be used in skeletally mature patients in levels C2-T1 in conjunction with fixation for ACDF (anterior cervical discectomy and fusion) procedures. The company announced it received FDA approval on September 8, 2021.

Advantage-C™ was developed to optimize fusion while maintaining elasticity that is similar to bone and radiolucency of the cage body. President Amit Sinha stated, “We are looking forward to a successful launch of Advantage-C™ and the myriad of efficiencies this device will bring to both surgeons and hospital systems”

He added, “Advantage-C is the basis for our rapidly growing interbody platform that will see continued innovation and product releases over the next year.” CEO Rob Anderson added, “Our growing line of interbody devices further drives home our commitment to bring cost-effective spinal solutions that consistently provide superior clinical results to the market. On behalf of the executive team, I am very impressed how quickly our R&D team worked to bring this device to market.”

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Recent News

CV Societies Propel Plans Forward for a New Board of Cardiovascular Medicine

“The open comment period is the time for cardiovascular physicians, allies in other medical specialties, patients, and others to make their voices heard on why an independent CV Board is the best path for cardiologists to stay up-to-date on best practices and evidence-based care, ensuring patients receive the best possible care,” said Jeffrey Kuvin, MD, president of the proposed Board’s new Board of Directors. “The field of cardiovascular medicine has evolved dramatically over the past few decades; now is the right time to develop an independent cardiovascular Board.”

Hyundai Bioscience Announces Clinical Development Plan for Niclosamide-based Metabolic Anticancer Drug Targeting P53 Mutation Cancer

Sang-ki Oh, CEO of Hyundai Bioscience, stated, "Niclosamide-based metabolic anticancer drug candidate will be the first P53-targeting anticancer treatment that selectively kills p53 mutated cancer cells," and added, "Through our subsidiary ADM Korea, we plan to conduct clinical trials targeting cancer patients with intractable cancer caused by p53 mutations, which will be the first step of clinical development on niclosamide-based anticancer agent pipeline."

Sedana Medical Completes Patient Recruitment for INSPiRE-ICU 1 Clinical Trial in the US

Peter Sackey further elaborated: "Once the 30-day follow-up of all patients is complete, we will enter into an intense phase of final monitoring, data cleaning and transfer to our statistician team for analysis. In parallel, the long-term outcomes at 3 and 6 months will be collected centrally by the Critical Illness, Brain Dysfunction, and Survivorship team at Vanderbilt Medical Center. With this parallel approach, we expect topline results in the autumn of this year and a swift regulatory submission in Q1, 2025".

Health / Lifestyle

Articles of Interest

Stay Connected

spot_img

About Medical Device News Magazine

About Medical Device News Magazine. A digital publication founded in 2008 located in the United States. The publication is one of the industry’s leading sources of medical device and biotech industry updates. Medical Device News Magazine is easily accessible 24/7/365 and is a fast 1, 2, 3 easy read! Our purpose is...

By using this website you agree to accept Medical Device News Magazine Privacy Policy